Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation

Journal of Neurochemistry

Volumn 72, Issue 3, 2000, Pages 1161-1169

  Marutle, Amelia ^a   Warpman, Ulrika ^a,b   Bogdanovic, Nenad ^a   Lannfelt, Lars ^a   Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UF   (Sweden)

Author keywords

Alzheimer's disease; Neurofibrillary tangles; Neuronal plaque; Nicotinic receptors; Swedish amyloid precursor protein 670 671 mutation; 3H Epibatidine; 3H Nicotine

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; EPIBATIDINE; NICOTINE; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE;

AGED; ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; NEUROFIBRILLARY TANGLE; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN DEFECT; SENILE PLAQUE;

EID: 0032974888     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0721161.x     Document Type: Article

References (50)

1. Auld D., Kar S., and Quirion R. (1998) β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci. 21, 43-49.
2. Axelman K., Basun H., Winblad B., and Lannfelt L. (1994) A clinical and genealogical investigation of a large Swedish Alzheimer family with a codon 670/671 amyloid precursor protein mutation. Arch. Neurol. 57, 1193-1197.
3. 3H]nicotine binding sites in human brain. J. Neurochem. 50, 1243-1247.
4. Bogdanovic N. and Morris J. H. (1995) Diagnostic criteria for Alzheimer's disease in multi-centre brain banking, in Neuropatholagical Diagnostic Criteria for Brain Banking (Cruz-Sandéz R. and Cuzner M. L., eds), pp. 20-29. IOS Press, Amsterdam.
5. Citron M., Oltersdorf T., Haass G., McConlogue L., Hung A., Seubert P., Vigo-Pelfrey C., Lieberburg I., and Selkoe D. (1992) Mutation of the β-amyloid precursor protein in familial AD increases β-protein production. Science 360, 672-674.
6. Corder E. H., Saunders N. J., Risch W. J., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Rimmler J. B., Locke P. A., Conneally P. M., Schmader K. E., Small G. W., Roses A. D., Haines J. L., and Pericak-Vance M. A. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180-184.
7. Court J. A., Lloyd S., Perry R. H., Griffiths M., Morris C., Johnson M., McKeith I., and Perry E. (1996) The nicotinic cholinergic system and β-amyloidosis, in Alzheimer's Disease: From Molecular Biology to Therapy (Becker R. and Giacobini E., eds), pp. 275-279. Birkhäuser, Boston.
8. Coyle J. T., Price D. L., and DeLong M. R. (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219, 1184-1190.
9. DeKosky S., Harbaugh R., Schmitt F., Bakay R., Chui H., Knopman D., Reeder T., Shetter A., Senter H., Markesbery W., and Intraventricular Bethanecol Study Group (1992) Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological and cognitive correlation. Ann. Neurol. 32, 625-632.
10. Dewji N. and Singer S. (1996) Genetic clues to Alzheimer's disease. Science 271, 159-160.
11. Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., and Lindstrom J. (1995) Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 48, 774-782.
12. 2+ mobilization in mouse C2C12 myotubes. Cell Calcium 18, 41-50.
13. Gray E. G. and Whittaker V. P. (1962) The isolation of nerve endings from brain in an electron microscopic study of cell fragments derived by homogenization and centrifugation. J. Anat. 96, 79-88.
14. Hardy J. (1996) New insight into the genetics of Alzheimer's disease. Ann. Med. 28, 255-258.
15. Kar S., Seto D., Gaudreau P., and Quirion R. (1996) Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J. Neurosci. 16, 1034-1040.
16. Lannfelt L. (1996) Genetics of Alzheimer's disease. Acta Neurol. Scand. Suppl. 168, 25-28.
17. Lannfelt L., Bogadanovic N., Appelgren H., Axelman K., Lillius L., Hansson G., Shenk D., Hardy J., and Winblad B. (1994) Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neurosci. Lett. 168, 254-256.
18. Levin E. D. (1992) Nicotinic system and cognitive function. Psychopharmacology (Berl.) 108, 417-431.
19. Lowry O. H., Rosebrough N. J., Farr A. L., and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
20. 3H]epibatidine. Brain Res. 801, 143-149.
21. 2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16, 409-414.
22. McGee D. and Role L. (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57, 521-546.
23. 3H]epibatidine. Med. Chem. Res. 4, 528-537.
24. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
25. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G., Berg L., and participating CERAD neuropathologists (1991) The Consortium to Establish a Registry for AD (CERAD). Part II: Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 41, 479-486.
26. Mullan J., Crawford F., Axelman K., Houlden H., Lillius L., Winblad B., and Lannfelt L. (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat. Genet. 1, 345-347.
27. Newhouse P. A., and Potter A, (1994) The role of nicotinic systems in the cognitive disorder of Alzheimer's disease, in Alzheimer's Disease: Therapeutic Strategies (Giacobini E. and Becker R., eds), pp. 191-195. Birkhäuser, Boston.
28. Nitsch R. M. and Growdon J. H. (1994) Role of neurotransmission in the regulation of amyloid β-protein precursor processing. Biochem. Pharmacol. 47, 1275-1284.
29. Nitsch R. M., Slack B. E., Wurtman R. J., and Growdon J. H. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307.
30. Nordberg A. (1994) Human nicotinic receptors - their role in aging and dementia. Neurochem. Int. 25, 93-97.
31. Nordberg A., Alafuzoff I., and Winblad B. (1992) Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31, 103-111.
32. 11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9, 21-27.
33. Nordberg A., Viitanen M., Almkvist O., Basun H., Wahlund L.-O., Lannfelt L., and Winblad B. (1995b) Longitudinal positron emission tomographic studies in families with chromosome 14 and 21 encoded Alzheimer's disease, in Research Advances in Alzheimer's Disease and Related Disorders (Iqbal K., Mortimer J., Winblad B., and Wiesniewski H., eds), pp. 243-249. John Wiley & Sons, Chichester.
34. Nybäck H., Nordberg A., Långström B., Halldin C., Hartvig P., Åhlin A., Swahn C.-G., and Sedvall G. (1989) Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography. Prog. Brain Res. 79, 313-319.
35. 3H-nicotine) receptor binding in human brain: characterization and involvement in cholinergic neuropathology. Neurosci. Res. Commun. 5, 117-124.
36. Perry E. K., Morris C. M., Court J. A., Cheng A., Fairbairn A. F., McKeith I. G., Irving D., Brown A., and Perry R. H. (1995) Alteration in nicotinic binding sites in Parkinson's disease, Lewy body dementia, and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64, 385-396.
37. Pirtillä T., Soininen H., Mehta P. D., Heinonen O., Lehtimäki T., Bogdanovic N., Paljärvi L., Kims K. S., Kosunen O., Winblad B., Reikkinen P., and Wiesniewski H. M. (1997) Apolipoprotein E genotype and amyloid load in Alzheimer's disease and control brains. Neurobiol. Aging 18, 121-127.
38. Poirier J., Delisle M. C., Quirion R., Aubert I., Farlow M., Hui S., Bertrand P., Nalbantaoglu J., and Gilfix B. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. USA 92, 12260-12264.
39. Rubboli F., Court J. A., Sala C., Morris C., Perry E., and Clementi F. (1994) Distribution of nicotinic receptor subtypes in the human brain. Eur. J. Neurosci. 43, 1596-1604.
40. Salmon A. R., Marcinowski K. J., Friedland R. P., and Zagorski M. G. (1996) Nicotine inhibits amyloid formation by the β-peptide. Biochemistry 35, 13568-13578.
41. Sargent P, B. (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16, 403-443.
42. Schmechel D. E., Saunders A. M., Strittmatter W. J., Grain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D., and Roses A. D. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 9649-9663.
43. Soininen H., Lehtovirta M., Helisalm S., Linnaranta K., Heinonen O., and Riekkinen P. (1995) Increased acetylcholinesterase activity in the CSF of Alzheimer patients carrying apolipoprotein ε4 allele. Neuroreport 6, 2518-2529.
44. Stephenson J. (1997) Researchers find evidence of a new gene for late-onset Alzheimer's disease. JAMA 277, 775.
45. Strittmatter W., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., and Salveson G. S. (1993) Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.
46. Svensson A.-L., Warpman U., Hellström-Lindahl E., Bogdanovic N., Lannfelt L., and Nordberg A. (1997) Nicotinic receptors, muscarinic receptors and cholinesterase acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci. Lett. 232, 1-4.
47. Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A., and Katzman R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlation of cognitive impairment. Ann. Neurol. 30, 572-580.
48. Warpman U. and Nordberg A. (1995) Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains. Neuroreport 6, 2419-2423.
49. Yankner B. A., Duffy L. K., and Kirschner D. A. (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250, 279-282.
50. (25 35) in hippocampal cultures. Neuroreport 8, 513-517.